Industry layoffs surged last year, claiming about 14,000 jobs across biopharma. While many hoped 2024 would be a turning point, workforce cuts have continued and the worst might not be over, according to Arda Ural, EY Americas industry markets leader, health sciences and wellness.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,